Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Cellectis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
SIRION Biotech GmbH Licensed Its LentiBOOST™ Transduction Technology to Cellectis
Details : Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Cellectis
Deal Size : Undisclosed
Deal Type : Licensing Agreement